Recent advances in CRISPR-Cas system for the treatment of genetic hearing loss

Ge Yin; Xiao-Hui Wang; Yu Sun

Recent advances in CRISPR-Cas system for the treatment of genetic hearing loss

Am J Stem Cells. 2023 Aug 15;12(3):37-50. eCollection 2023.

Authors

Ge Yin¹, Xiao-Hui Wang¹, Yu Sun^{1

2

3}

Affiliations

¹ Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan 430022, Hubei, China.
² Hubei Province Key Laboratory of Oral and Maxillofacial Development and Regeneration Wuhan 430022, Hubei, China.
³ Institute of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan 430022, Hubei, China.

PMID: 37736272
PMCID: PMC10509501

Abstract

Genetic hearing loss has emerged as a significant public health concern that demands attention. Among the various treatment strategies, gene therapy based on gene editing technology is considered the most promising approach for addressing genetic hearing loss by repairing or eliminating mutated genes. The advent of the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas system has revolutionized gene therapy through its remarkable gene editing capabilities. This system has been extensively employed in mammalian gene editing and is currently being evaluated through clinical trials. Against this backdrop, this review aims to provide an overview of recent advances in utilizing the CRISPR-Cas system to treat genetic hearing loss. Additionally, we delve into the primary challenges and prospects associated with the current application of this system in addressing genetic hearing loss.

Keywords: Cas13; Cas9; Genetic hearing loss; clustered regularly interspaced short palindromic repeats (CRISPR); gene editing; gene therapy.

Publication types

Review